You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Point-of-care antigen detection assay for early diagnosis of Ebola virus disease (EVD)

    SBC: Inbios International Inc            Topic: NIAID

    Project Summary Ebolavirus spp. cause a severe hemorrhagic fever known as Ebola virus disease (EVD). EVD is a serious public health concern, both as an emerging infectious disease and a potential biothreat. The 2013-2016 Ebola pandemic in West Africa brought global attention to the challenges associated with controlling an Ebola. The ongoing outbreak in the Democratic Republic of Congo, which rece ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Drug target identification using CRISPRi/a screening

    SBC: BIOIO, LLC            Topic: 400

    ABSTRACT As phenotypic screening makes a comeback in drug discovery, its major issue is drug target identification. There aren’t good generalizable approaches to do target identification for compounds of interest. Identifying how a new drug works at the molecular level is critical for improving it, which is often needed to give it the best chance of ultimately being both safe and effective in pa ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. CBTpro: Scaling up CBT for psychosis using simulated patients and spoken language technologies

    SBC: Lyssn.IO, INC.            Topic: 104

    Psychosis resulting from schizophrenia spectrum disorders and major mood disorders is one of the most disabling health concerns worldwide. Evidence-based psychotherapeutic interventions are recommended as standard of care by national psychosis treatment guidelines but are rarely accessible. Cognitive Behavioral Therapy for psychosis (CBTp) is the most well-researched psychotherapy for psychotic di ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Development of wearable technology to enable therapy personalization of 177Lu DOTATATE for neuroendocrine tumors

    SBC: PRECISION SENSING LLC            Topic: 102

    For patients with metastatic, somatostatin-receptor-2 (SSTR2) positive neuroendocrine tumors (NETs), targeted therapy using 177Lu-DOTATATE greatly increases progression-free survival (PFS), as shown in the NETTER-1 trial. PFS at month 20 was 65.2% (95% CI, 50.0 - 76.8) for midgut NETs treated with 177Lu- DOTATATE alone compared to 10.8% (95% CI, 3.5 - 23.0) in a control group receiving 60 mg octre ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Multi-Modal Venus Clot Removal Device

    SBC: Caeli Vascular LLC            Topic: NHLBI

    ABSTRACTThis Phase I STTR application from Caeli Vascular, LLC entails a 12-month period focused on the development of a novel endovascular venous thrombectomy device. The PI is a vascular surgeon with biomedical research and entrepreneurship experience, and is supported by a team of highly qualified investigators, including a vascular biologist, neurosurgeon, veterinarian, biomedical engineer, me ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Multi-fold increase in the production of pharmaceutical insulin with Microbial Stem Cell Technology

    SBC: ASIMICA, INC.            Topic: 300

    PROJECT SUMMARY / ABSTRACT The goal of this project is to demonstrate the feasibility of a novel technology that is expected to boost yields from pharmaceutical industrial insulin production by greater than four-fold over conventional methods. Higher yields will lower production costs, generating savings that will ultimately be passed onto the millions of diabetic patients who require daily insuli ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. New Inhibitors of HIV latency reactivation

    SBC: Ithax Pharmaceuticals Inc            Topic: NIAID

    ABSTRACTCompany - Ithax Pharmaceutical is a new spin-off biotechnology company, located in Seattle, focused on developing proprietary small molecule chemistry to target RNA. The experience of its founders spans virology, drug design and RNA structure and function, and gives it a unique technological expertise in the RNA-targeting space. Their commercial expertise includes the successful founding, ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. PIXUL-FFPE:High throughput platform for chromatin and DNA sample preparation from formalin fixed paraffin embedded (FFPE) tissue samples.

    SBC: Matchstick Technologies Inc.            Topic: 172

    Formalin fixed paraffin-embedded (FFPE) tissue archives represent the largest clinically annotated human specimen repository. The estimated millions of available FFPE tissue samples provide vast resource for the discovery of disease epigenetic pathways, biomarkers and drug targets, And yet, these samples are highly underutilized because current methods for extracting molecular information from FFP ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. A Sparse-readout Quantitative PET scanner for breast cancer therapy optimization

    SBC: PET/X LLC            Topic: 102

    Our goal is to improve how breast cancer therapies are matched to individual breast-cancer patients with early- stage disease by providing a timely evaluation of therapy efficacy during the window of opportunity between diagnosis and surgical resection. In so doing, we aim to direct patients more quickly to effective therapies, improving outcomes, and reducing toxicities and healthcare costs from ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Translational development of specialized NK cells for cancer immunotherapy

    SBC: Indapta Therapeutic            Topic: 102

    Project Summary Abstract The annual incidence of head and neck cancers worldwide is more thancases with arounddeaths each yearand it is estimated that inthere will benew cases of non Hodgkin lymphoma with an estimateddeaths this yearIn this proposalwe describe a strategy to use a novel subset of natural killer cellsg NK cellsallogeneically for cancer therapyWe hypothesize that expansion and adopti ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government